These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33739967)

  • 21. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 23. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment.
    Tshuma N; Glynn N; Evanson J; Powles T; Drake WM
    Eur J Cancer; 2018 Nov; 104():247-249. PubMed ID: 30377030
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments.
    Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Yu T; Bharmal M
    Value Health; 2021 Aug; 24(8):1137-1144. PubMed ID: 34372979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?
    Alkassis M; Sarkis J; Tayeh GA; Kourie HR; Nemer E
    Immunotherapy; 2021 Apr; 13(6):459-463. PubMed ID: 33557589
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Necchi A; Giardiello D; Mariani L
    Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
    [No Abstract]   [Full Text] [Related]  

  • 33. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
    Gupta S; Kamat AM
    Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three more immune checkpoint inhibitors for advanced bladder cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
    [No Abstract]   [Full Text] [Related]  

  • 36. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
    Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
    Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
    [No Abstract]   [Full Text] [Related]  

  • 37. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic characterization of bladder cancer.
    Fradet Y
    Eur Urol; 1998; 33 Suppl 4():5-6. PubMed ID: 9615196
    [No Abstract]   [Full Text] [Related]  

  • 39. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Gakis G
    Eur Urol; 2021 May; 79(5):702. PubMed ID: 33390284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.